In short
This article discusses a clinical trial investigating the use of CSM-GW, a type of mesenchymal stem cell (MSC), in treating patients with severe septic shock. The study aims to determine how these stem cells, when administered early in the course of septic shock, affect organ failure and patient outcomes. This Phase II trial compares the effects of CSM-GW to a control group, focusing on patients with community-acquired septic shock and multiple organ failures.
At a glance
- Drug Name
- CSM-GW (Mesenchymal Stem Cells)
- Trial Phase
- Phase II
- Condition Studied
- Severe community-acquired septic shock
- Main Objective
- Effect on organ failure (SOFA score at Day 7)
- Key Inclusion Criteria
- Adults with septic shock < 12 hours, ≥ 2 organ failures
- Key Exclusion Criteria
- Nosocomial shock, immunosuppression, severe respiratory failure
- Dosage
- 1 million cells/kg, max 80 million cells
- Administration
- Intravenous injection
- Safety Monitoring
- Immediate effects and adverse events up to 90 days
What is CSM-GW?
CSM-GW is an experimental medication that contains mesenchymal stem cells (MSCs). These are special cells that can develop into different types of tissues in the body. The specific MSCs used in CSM-GW are derived from Wharton's Jelly, which is a gelatinous substance found in the umbilical cord. This medication is currently being studied as a potential treatment for a severe condition called septic shock.
What condition does CSM-GW treat?
CSM-GW is being investigated for the treatment of severe septic shock. Septic shock is a life-threatening condition that occurs when your body's response to an infection causes widespread inflammation and organ failure. It's considered severe when it leads to at least two organ failures (not including the circulatory system) within 12 hours of onset.
Symptoms of severe septic shock may include:
- Difficulty breathing
- Confusion or altered mental state
- Decreased urine output
- Low platelet count
- Liver problems
How does CSM-GW work?
While the exact mechanism is still being studied, mesenchymal stem cells like those in CSM-GW are believed to have anti-inflammatory and tissue-repairing properties. In the case of septic shock, these cells might help to:
- Reduce excessive inflammation in the body
- Support the repair and regeneration of damaged organs
- Modulate the immune system's response to the infection
By potentially addressing these aspects, CSM-GW aims to improve organ function and overall outcomes for patients with severe septic shock.
How is CSM-GW administered?
CSM-GW is given as an intravenous injection, which means it's delivered directly into the bloodstream through a vein. The medication comes in the form of a suspension for injection. In the current clinical trial, patients receive a single dose of 1 million cells per kilogram of body weight (with a slight variation allowed), up to a maximum of 80 million cells.
Current Clinical Trial
CSM-GW is currently being studied in a Phase II clinical trial called CHOC-MSC. This trial aims to determine the effects of mesenchymal stem cells when given in the early stages of septic shock. The main goals of the study include:
- Assessing how CSM-GW affects organ failure, as measured by a score called SOFA (Sepsis Organ Failure Assessment).
- Determining if CSM-GW can help patients recover from organ failure more quickly.
- Evaluating the impact of CSM-GW on patient survival rates and length of stay in intensive care.
- Studying the safety of CSM-GW both immediately after injection and up to 3 months later.
Potential Benefits
If successful, CSM-GW could potentially offer several benefits for patients with severe septic shock:
- Improved organ function
- Faster recovery from organ failure
- Reduced mortality rates
- Shorter stays in intensive care
However, it's important to note that these potential benefits are still being investigated and have not yet been proven.
Safety Considerations
As with any experimental treatment, there are potential risks and side effects associated with CSM-GW. The clinical trial is closely monitoring for any adverse events, including:
- Temporary decrease in blood oxygen levels
- Increase in pulmonary artery pressure
- Shivering or fever
- Pulmonary embolism (a blood clot in the lungs)
These potential side effects are being carefully watched for up to 2 hours after the injection of CSM-GW. The trial is also monitoring for any other adverse events for up to 90 days after treatment.
It's crucial to understand that CSM-GW is still an investigational treatment. Its safety and effectiveness are not yet fully established, and it is not currently approved for general use outside of clinical trials.